PDCD1 and ovarian carcinoma: Clinically, a Phase I trial using anti-CD40 IgG2 mAb CDX-1140 with anti-PD-1 IgG4 mAb Pembrolizumab (Keytruda) is currently recruiting ovarian cancer patients (NCT03329950).